MDM4 was found to be up-regulated in invasive breast carcinoma (by 14.2%), liver hepatocellular carcinoma (by 12.4%), retinoblastomas (by 65%), skin cutaneous melanomas (by 12%), and stage II–V melanomas (by > 65%) [3]. Here, MDM4 is linked to cutaneous melanoma.